Based on our results, we hypothesize that IM, a BCR-ABL1 tyrosine kinase inhibitor, combined with a PAK1/2 inhibitor facilitates eradication of CML-CP cells. This evidence concerns the gene PAK1 and chronic myelogenous leukemia, BCR-ABL1 positive.